These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 32291212)

  • 81. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.
    Suh KJ; Kim SH; Kim YJ; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
    Cancer Immunol Immunother; 2018 Mar; 67(3):459-470. PubMed ID: 29204702
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
    Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
    Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
    Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
    [TBL] [Abstract][Full Text] [Related]  

  • 84. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
    Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
    Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
    Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
    ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
    Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
    Future Oncol; 2024; 20(22):1553-1563. PubMed ID: 38629593
    [No Abstract]   [Full Text] [Related]  

  • 87. Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.
    Bowman L; Tiu R; Smyth EN; Willard MD; Li L; Beyrer J; Han Y; Singh A
    Clin Lung Cancer; 2021 Jan; 22(1):32-41.e1. PubMed ID: 33221173
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
    Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
    [TBL] [Abstract][Full Text] [Related]  

  • 90. CD8
    Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
    Auclin E; Benitez-Montanez J; Tagliamento M; Parisi F; Gorria T; Garcia-Campelo R; Dempsey N; Pinato DJ; Reyes R; Albarrán-Artahona V; Dall'Olio F; Soldato D; Hendriks L; Nana FA; Tonneau M; Lopez-Castro R; Nadal E; Kazandjian S; Muanza T; Blanc-Durand F; Fabre E; Castro N; Arasanz H; Rochand A; Besse B; Routy B; Mezquita L
    Lung Cancer; 2023 Apr; 178():116-122. PubMed ID: 36812760
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):563-8. PubMed ID: 25257958
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Oh MS; Guzner A; Wainwright DA; Mohindra NA; Chae YK; Behdad A; Villaflor VM
    Clin Lung Cancer; 2021 Jan; 22(1):e57-e62. PubMed ID: 32900613
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
    Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; Dingemans AM; Planchard D; Cozic N; Cassard L; Lopes G; Chaput N; Arbour K; Besse B
    Eur J Cancer; 2021 Jul; 151():211-220. PubMed ID: 34022698
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy.
    Matsubara T; Hirai F; Yamaguchi M; Hamatake M
    Anticancer Res; 2021 Oct; 41(10):5157-5163. PubMed ID: 34593467
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study.
    Li Y; Zhao J; Li R; Yao X; Dong X; Zhang R; Li Y
    Neoplasia; 2024 Nov; 57():101043. PubMed ID: 39226660
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
    Tamura K; Okuma Y; Nomura S; Fukuda A; Masuda K; Matsumoto Y; Shinno Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):216. PubMed ID: 38668936
    [TBL] [Abstract][Full Text] [Related]  

  • 98. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
    Molinier O; Besse B; Barlesi F; Audigier-Valette C; Friard S; Monnet I; Jeannin G; Mazières J; Cadranel J; Hureaux J; Hilgers W; Quoix E; Coudert B; Moro-Sibilot D; Fauchon E; Westeel V; Brun P; Langlais A; Morin F; Souquet PJ; Girard N
    ESMO Open; 2022 Feb; 7(1):100353. PubMed ID: 34953398
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor.
    He LN; Fu S; Ma H; Chen C; Zhang X; Li H; Du W; Chen T; Jiang Y; Wang Y; Wang Y; Zhou Y; Lin Z; Yang Y; Huang Y; Zhao H; Fang W; Zhang H; Zhang L; Hong S
    ESMO Open; 2022 Dec; 7(6):100630. PubMed ID: 36442353
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
    Banna GL; Tiseo M; Cortinovis DL; Facchinetti F; Aerts JGJV; Baldessari C; Giusti R; Bria E; Grossi F; Berardi R; Morabito A; Catino A; Genova C; Mazzoni F; Gelibter A; Rastelli F; Macerelli M; Chiari R; Gori S; Mansueto G; Citarella F; Cantini L; Rijavec E; Bertolini F; Cappuzzo F; De Toma A; Friedlaender A; Metro G; Pensieri MV; Porzio G; Ficorella C; Pinato DJ; Cortellini A; Addeo A
    Thorac Cancer; 2022 Feb; 13(3):483-488. PubMed ID: 34939342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.